Compare DLNG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLNG | MOLN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Greece | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 164.2M |
| IPO Year | 2013 | 2021 |
| Metric | DLNG | MOLN |
|---|---|---|
| Price | $3.87 | $4.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 54.7K | 4.3K |
| Earning Date | 03-05-2026 | 03-05-2026 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | ★ 30.14 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $158,275,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.37 | $999.99 |
| P/E Ratio | $3.02 | ★ N/A |
| Revenue Growth | ★ 4.34 | N/A |
| 52 Week Low | $3.18 | $3.36 |
| 52 Week High | $5.35 | $5.81 |
| Indicator | DLNG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 48.40 |
| Support Level | $3.70 | $4.11 |
| Resistance Level | $4.18 | $4.28 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 50.00 | 28.21 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.